Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.

Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.

Publication date: May 15, 2019

Circulating levels of IgM anti-CD64, an immunosuppressive antibody recently identified in long-term stable multiple sclerosis (MS) patients, were found to fluctuate over time in MS patients. Antibody-positive patients showed a significantly lower annualized relapse rate value as well as reached sustained disability worsening and had a relapse in a significantly longer median time than those without antibody. Disease-modifying therapies (DMTs) only were the covariate influencing both the relapse occurrence and the disability accrual. Serum IgM anti-CD64 levels are associated with maintenance of clinical stability in MS and may be tested as a candidate biomarker predictive of benign course and favourable long-term response to DMTs treatment.

Annunziata, P., Masi, G., and Cioni, C. Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients. 18002. 2019 J Neuroimmunol (330):

Concepts Keywords
Antibody CD64
Benign Immunology
Biomarker Immunoglobulin M
Covariate Antibody
Disability Immune system
IgM Multiple sclerosis
Immunosuppressive Biomarkers
Multiple Sclerosis Glycoproteins
Relapse Medical specialties
Branches of biology
Medicine
MS

Semantics

Type Source Name
disease MESH relapse
disease DOID multiple sclerosis
disease MESH multiple sclerosis
gene UNIPROT CD40LG
gene UNIPROT FCGR1A

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *